Patent · US Active

Method for prevention of platelet aggregation employing and RGD-enriched gelatine-like protein

US8080515B2 · kind B2 · utility

4Cited by
9References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 30, 2009
Grant dateDec 20, 2011
Priority date
Expiry dateJan 20, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2533/54
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif. Preferably the RGD-enriched gelatines are prepared by recombinant technology, and have a sequence that is derived from a human gelatine or collagen amino acid sequence. The invention also relates to RGD-enriched gelatines that are used for attachment to integrins. In particular The RGD-enriched gelatines of the invention are suitable for coating a cell culture support for growing anchor-dependant cell types. Further, the RGD-enriched gelatines of the invention may find use in medical applications, in particular as a coating on implant or transplant material or as a component of drug delivery systems.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.